Stay Informed. Stay Competitive with FREE Insights on the Stock Market, Dow 30 & Emerging Opportunities. Get Free Email Updates

Stay Competitive With Stock Market Updates!

Get Free Updates

Vista Partners Weekly Market Wrap Published On 9/11 – $AAPL $AFRM $TSLA, Quizlet IPO & More…

By John F. Heerdink, Jr.
“Life is a dream for the wise, a game for the fool, a comedy for the rich, a tragedy for the poor.” – Sholom Aleichem, Russian Writer, March 2, 1859 – May 13, 1916

Happy Saturday All!

I hope that you had great success investing in the markets during this Labor Day holiday shortened week and that you are out enjoying your time off this second weekend in September.  Thank you again for your attention and I look forward to personally catching up with each of you soon. My thoughts and good wishes also go out to all families that lost loved ones on 9/11, now an amazing 20 years ago to date.  This unprecedented tragedy where four coordinated terrorist attacks by the militant Islamist terrorist group al-Qaeda was waged against the United States of America on the morning of Tuesday, September 11, 2001 should never be forgotten.

As for the markets, it was an overall pullback kind of week across the board as all indices moved lower. A number of negative headlines seemed to take the spotlight and at least clouded investors minds i.e. a reduced Q4 & 2021 GDP forecast surfaced from leading ibank Goldman Sachs (GS) increasing growth concerns on the shoulders of the surge of the Delta variant & unresolved supply chain issues & where 71 investment firms still see 6% growth this year, however that is off of the 7% originally envisioned, the infrastructure plan also lost support from a key democrat, Senator Manchin, for at least anything over $1.5T, Janet Yellen was loud again, this time about her fears about not resolving the debt-ceiling, enhanced unemployment benefits expired, crypto values took a nosedive, Apple (AAPL, off 3.05% for the week) lost a case & is now being forced to allow developers to create their own payment options, & finally increased global growth concerns appeared as central banks are lifting their foot off the gas pedal. The indices, in turn, closed lower as follows: the S&P 500 closed at 4,458.58 (-1.7%), dropping for 5-consecutive day, but remains up 18.7% YTD, the Dow 30 closed at 34,607.72 (-2.2%) & remains up 13.1% YTD, & the Nasdaq closed at 15,115.49 (-1.6%) & remains up 17.3% YTD. The small caps on the Russell 2000 also closed in negative territory at 2,227.55 (-2.8%) & remains up 12.8% YTD. The MicroCaps moved higher as the iShares Micro-Cap ETF (IWC) closed at $146.29 (-2.92%) & remains up 23.30% YTD.

We also saw all 11 sectors close in the red with the real estate sector off 3.9%, the health care sector off 2.7%, & the industrials sector falling 2.5% to lead all sectors. Basically, there was no real place to hide this week. In contrast to the global growth worries narrative, oil prices managed to close higher at $69.62, rising .5% for the week, and now are up 43.5% YTD. I just paid $4.99/gallon to fill up my car. I may need to buy the EV from Tesla (TSLA, $736.27, +.53% over the week) soon…


Many more macroeconomic reports surfaced again this week. On Tuesday, the Fed’s Beige Book confirmed that economic growth moved lower to a moderate pace in early July through August pointing to the spread of the Delta variant. The consumer credit report confirmed a rise by $17B in July. The job openings report showed a rise to an all-time record-high of 10.934M in July. The weekly MBA Mortgage Applications Index fell by 1.9%. On Wednesday, the consumer credit report confirmed a rise by $17B in July, but missed expectations. The job openings report also showed a rise to an all-time record-high of 10.934M in July. The weekly MBA Mortgage Applications Index fell by 1.9%. On Thursday, the initial claims report for the week ending September 4, confirmed a drop by 35k to 310k, while the continuing claims report for the week ending August 28 confirmed a drop by 22k to 2.783M. On Friday, the Producer Price Index for final demand report showed a rise by .7% M/M in August The index for final demand report confirmed a rise by .6% M/M, while on a Y/Y basis, the Producer Price Index for final demand report came in at +8.3% on an unadjusted basis. The index for final demand moved up to 6.7%. The Wholesale inventories report showed a rise by .6% M/M in July.

The yield curve widened a bit this week. The 10-yr yield ended up 2 basis points wk/wk to close at 1.34%, while the 2-yr was flat wk/wk closing at .21%. The U.S. Dollar Index moved lower again from 92.68 to close at 92.62.

Next week, the macroeconomic schedule will serve the Retail Sales growth report, the Michigan Sentiment index report, & the inflation report.


Boeing’s 737 MAX Aircraft Wins Approval Top Resume Operations In Singapore

Hurricane Hit Louisiana Region Receives $1 Million Assistance From United Health Foundation

Disney ($DIS) Consolidating Streaming Services To Disney Bundle

The Home Depot’s Chief Sustainability Officer Ron Jarvis To Host An ESG

Verizon Announces Increased Cash Dividend Payable November 1, 2021

Apple Puts Hold On Device Child Safety Updates


The FAANG’s weekly returns were as follows: Apple (AAPL) closed at $148.97, -3.05%, Amazon (AMZN) closed at $3,469.15, +.17% for the week, Alphabet (GOOG) closed at $2,838.42, -1.59% for the week, Facebook (FB) closed at $378.69, +.91% this week & Netflix (NFLX) closed at $598.72/share, +1.73%. The MicroSectors FANG+ Index 3X Leveraged ETN (FNGU), which offers 3x leveraged exposure to an index of “FANG” companies, and other companies that exhibit similar characteristics, closed at $38.62, -2.08% for the week.


Leading EV car maker Tesla (TSLA) moved higher to close at $736.27, +.53% & shares of Ford Motor Co. (F) closed at $12.68, -2.54% for the week.

Microsoft (MSFT) closed at $295.71, -1.81% for the week after recently recording a new record high of $305.84.

Chip making giant NVIDIA Corporation closed $224.78, +.37% for the week and establishing a new record high of $230.43. I recommend that you watch the video titled “5 reasons the world is running out of Chips” that I have included in this weeks videos at the end of this newsletter.

MongoDB, Inc. (NASDAQ: MDB), the leading, modern general purpose database platform reported Q2 Fiscal 2022 report and recorded Total Revenue of $199 million, up 44% Year-over-Year & Continued Strong Customer Growth with Over 29,000 Customers as of July 31, 2021 last week. Shares of MDB closed at $488.80, +21.7% this week.

Cathie Wood’s ARK Innovation ETF (ARKK) closed at $120.46, -3.5% for the week.

The Technology Select Sector SPDR Fund (XLK) closed at $156.63, -.99% for the week.

ADT, Inc, (ADT) closed at $8.11, -6.67% for the week. Hopefully Google’s (GOOG) partner is beginning to regain some form. 

Affirm (AFRM), a payment network that ’empowers’ consumers and helps merchants drive growth, closed at $123.70, +34.4% on Friday after beating Wall Street’s expectations and issuing upwards guidance on their toppling.

San Francisco-based edtech startup, Quizlet, a flashcard tool turned artificial intelligence-powered tutoring platform, is reportedly planning an initial public offering.  The last time it was valued officially was about 1-year ago and it came in at $1 billion.


Disney (DIS) closed at $184.12, +1.24% for the week. Recently, DIS reported a better than expected Q3 earnings report. Disney is now moving content from its streaming service Hotstar to its ESPN+ and Hulu streaming platforms in the United States. Disney, with 174 million paying customers across its four streaming services, is slowly consolidating its content into a Disney Bundle, which will include ESPN+, Hulu, Disney+ and more than 100,000 movies, TV episodes as well as sports events. Sports content from Hotstar will move to ESPN+, and Hotstar movies, as well as TV shows, will migrate to Hulu.The Disney Bundle, which starts at $13.99 per month, will cost subscribers at least $167.88 for a year. Disney’s streaming users growth (Disney+) blasted through expectations checking in with 116M vs. the 113.1M. People cannot seem to do without their Star Wars and Marvel related content.


The Nasdaq Biotechnology ETF (IBB) closed at $173.23, -1.57% for the week, & remains up 14.35% YTD, the NYSE ARCA Biotech Index (^BTK) closed at 5,881.57, -2.29% for the week and remains up +2.48% YTD, & the SPDR S&P Biotech ETF (XBI) closed at $131.72, -3.52% & is now down 6.44% for the year. The XBI’s 52-wk range is $100.64-$174.79.


Gold prices headed higher again to close at $1,790, down $40 from the $1,830 close last week & silver prices closed lower at $23.78/oz., down $.97 from the $24.75/oz. close last Friday. Hecla Mining Company (NYSE: HL) closed $6.05, -1.47% for the week. 


AMC Entertainment (AMC), closed at $50.16, +13.02% for the week & GameStop (GME) closed at $190.41, -10.82% for the week. 

Virgin Galactic Holdings (SPCE) closed at $25.16, -3.39% settling significantly lower the relatively recent all-time high of $62.80.

Infamous ‘meme brokerage’ firm Robinhood Markets, Inc., (HOOD) moved higher this week closing at $41.17, -7.46% for the week.

Seanergy Maritime Holdings Corp. (SHIP) closed at $1.25, -4.58% this week . The ‘only pure-play Capesize ship-owner publicly listed in the US’, announced recently that its Board of Directors has authorized a share repurchase plan. Under the Plan, the Company may repurchase up to $17 million of its outstanding common shares, representing approximately 10% of the Company’s market capitalization as of August 10, 2021. Capsize rates continue to surge which should bold for them!


Bitcoin $BTC.X moved higher again this week eclipsing the $50k level while settling at 44,586.33, -4.75% over the week.


The markets will be back to a 5-day week next week. Sorry no holiday.


Please review our complete VP Watchlist that includes Apple (AAPL), Disney (DIS), Tesla (TSLA) & a select group of emerging names.  The pages will allow you to learn more and keep up with these companies daily.

For now, please see the updates from five of the emerging companies from the VP Watchlist below:

  • Shares of INmune Bio, Inc. (NASDAQ: INMB) moved significantly higher over the week closing at $21.40, -10.91% this week. The 52-wk range is $7.28 – $30.37. 
    • On Wednesday, Aug. 4th, INmune Bio, Inc. reported its financial results for the second quarter ended June 30, 2021 and provided a business update. Raymond J Tesi, M.D., CEO/CMO of INmuneBio (INMB) stated, “We continue our planning and setup for a Phase 2 clinical trial of our lead candidate, XPRO™ (Xpro1595™), in patients with mild Alzheimer’s disease, which we plan to initiate by year-end. We have already demonstrated that XPRO™ can reduce neuroinflammation and decreases biomarkers of neurodegeneration and improve synaptic function. If successful in Phase 2, we believe XPRO™ has the potential to be among the most significant advancements in the treatment of Alzheimer’s Disease (AD) and other neurodegenerative diseases in many years. At the Alzheimer’s Association International Conference last week, we introduced a new biomarker – Apparent Fiber Density (AFD), a measure of axonal integrity measured by MRI. XPRO™ increases AFD in patients receiving 1mg/kg/week. We believe the novel non-invasive white matter analytics of white matter free water and apparent fiber density will be very useful in the development of XPRO™ in AD, Treatment Resistant Depression (TRD) and the many other CNS indications we hope to attack in the future. Last month, we treated the first patient in the first Phase 1 clinical trial of our NK cell priming platform, INKmune, in high-risk myelodysplastic syndrome (MDS). We are calling INKmune a pseudokine because, in vitro, it converts the resting NK cells into memory-like NK cells that can kill cancer cells as well or better than NK cells treated cytokines such as IL-12, IL-15 and IL-18 alone or in combination.”
    • On July 26th, INmune Bio announced the design of its upcoming Phase 2 clinical trial of XProTM in patients diagnosed with mild Alzheimer’s disease (AD) at AAIC. The announcement was accompanied by the release of additional biomarker data from the Phase 1b AD trial that shows improvement in white matter (myelinated axons) that degenerate in AD patients. READ MORE. 
    • On July 22, LUMICKS, a leading next generation life science tools company renowned for its innovative platforms for Dynamic Single-Molecule and Cell Avidity analysis, announced that it has installed its ground-breaking z-Movi® Cell Avidity Analyzer at INmune Bi0. INmune Bio is employing the z-Movi cell avidity analysis platform to demonstrate that the mechanism of action of the tumor-priming is the increase in NK cell:tumor cell avidity. Early data acquired by the z-Movi support their hypothesis that increased cell avidity enhances NK cell killing of tumor cells. This allows screening of batches of INKmune for potency and provides a potential biomarker of in vivo activity by measuring the tumor avidity of NK cells isolated from patients before and after INKmune treatment.
    • On July 14th, INmune Bio announced that it has entered into a definitive agreement with one healthcare focused institutional investor and one family office for the purchase and sale of 1,818,182 shares of its common stock at a price of $22 per share for gross proceeds of approximately $40 million in a registered direct offering. The closing of the offering is expected to occur on or about July 16, 2021, subject to the satisfaction of customary closing conditions. A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering. INmune Bio intends to use the net proceeds from this offering for working capital and general corporate purposes and to advance the development of its product candidates and expand its pipeline. This includes the completion and data readout from the Company’s planned Phase 2 clinical trial of its lead clinical candidate, XPro1595, in patients suffering from Alzheimer’s disease, which is expected to commence by the end of 2021. “With this investment, we expect the Company’s Phase II program in Alzheimer’s disease is completely funded said RJ Tesi MD, CEO of Inmune Bio.
    • On July 12th,  INmune Bio, Inc. announced that the first patient has been treated in the company’s Phase 1 clinical trial of its Natural Killer (NK) cell priming platform, INKmune, as a potential treatment for high-risk myelodysplastic syndrome (MDS). This Phase 1 open label study will enroll nine patients with a confirmed diagnosis of MDS with excess blasts in a 3×3 dose escalation protocol. The primary endpoint is the safety and tolerability of INKmune when administered intravenously. Most secondary endpoints are biomarkers and include the change in percentage of blasts in peripheral blood and bone marrow, the change in autologous NK cell activity and functional maturity into tumor-induced memory-like NK cells in vivo. The overall response rate using WHO criteria, and duration of response will also be reported. READ MORE.
    • On July 7th, The Maxim Group’s analyst raised his price target from $32 to $42 today.
    • On June 14th, INMB announced that it had entered into a new $15M credit facility with Silicon Valley Bank (SVB) and an affiliate of SVB Financial Group. INmune intends to use the proceeds from the facility to partially fund the buyout of an option held by Xencor, Inc.(XNCR), resulting from INmune’s in-licensing of XPro1595 (now known by its generic name, pegipanermin) in October 2017. XPro1595 is a next-generation inhibitor of tumor necrosis factor (TNF) that uses a dominant-negativeTNF technology that is very different from approved TNF inhibitors that block the effects of both soluble and trans-membrane TNF. Pegipanermin neutralizes soluble TNF, without affecting trans-membrane TNF or TNF receptors. XPro1595 could have substantial beneficial effects in patients with Alzheimer’s and other neurodegenerative diseases by decreasing neuroinflammation. Total consideration to be paid to Xencor by INmune is $18.3 million, comprised of $15 million of cash and $3.3 million of INMB shares at a price of $17.14 resulting in the issuance of 192,533 shares. Pursuant to the original 2017 in-licensing agreement, INmune granted Xencor an option to purchase an additional number of shares of common stock equal to 10% of INmune’s fully diluted company shares for a period of seven years. The retirement of the Xencor option eliminates an estimated 2.1 million shares of potential future common stock dilution upon exercise of the option.

    • On May 18th, I hosted Immune Bio’s CEO RJ Tesi at the Tribe Public Presentation & Q&A Event for a fascinating discussion and his presentation titled “Advancing Treatment To Repair Our Aging Innate Immune System to Fight Alzheimer’s.” Please view the event video here. 

  • InMed Pharmaceuticals, Inc. (NASDAQ: INM) is leading clinical-stage pharmaceutical company developing cannabinoid-based drug candidates for high unmet medical needs and IntegraSyn, a proprietary and cost effective manufacturing approach for synthesized rare cannabinoids. Please visit the INM page at our website to learn more and check out the videos section too.  
  • Shares of InMed closed trading this week at $2.09, -13.28% for the week. The 52-wk range is $2.05 -$8.94.
    • I will be hosting the management team on the Tribe Public Network for a FREE Zoom-based Presentation & Q&A Event on September, 21 at 8:30am PT – 9am PT. the event is title “Accelerating The Commercialization of Rare Cannabinoids.” REGISTER now at INM.TribePublic.com.
    • Eric. A. Adams, President and CEO of INM, and Dr. Eric Hsu, Senior Vice President of Pre-Clinical Research & Development, will present at H.C. Wainwright Ophthalmology Virtual Conference on Tuesday, August 17, 2021. Mr. Adams and Dr. Hsu will provide an overview of InMed’s ocular program including INM-088, a topical eye drop formulation under development for the treatment of glaucoma. The active pharmaceutical ingredient (“API”) in INM-088 is cannabinol, also known as CBN, a rare cannabinoid showing promise in its potential to provide neuroprotection and to reduce intraocular pressure of the eye.

    • On July 9th, Roth Capital Partners analyst Scott Henry, CFA issued an update report with. BUY Rating titled, “INM: Favorable Take on BayMedica LOI” that includes a $11.50 12-Month Price Target.
    • On July 2, InMed announced that it had closed the previously announced private placement and after deducting the placement agent fees and estimated offering expenses payable by the Company, the Company received net proceeds of approximately US$11 million. H.C. Wainwright & Co. acted as the exclusive placement agent for the private placement. Under the terms of the private placement, an aggregate of 4,036,327 common shares (or common share equivalents in lieu thereof) and warrants to purchase up to an aggregate of 4,036,327 common shares were purchased, at an effective purchase price of US$2.973 per common share (or common stock equivalent in lieu thereof) and associated warrant. The warrants have an exercise price of US$2.848 per share, are exercisable immediately and have a term of five years. InMed intends to use the net proceeds from the offering to continue pipeline development, advance business development activities and for general working capital purposes.

    • On June 29th, INM announced that it has entered into a non-binding letter of intent (the “LOI”) to acquire BayMedica Inc. (“BayMedica”), a private company based in Nevada and California that specializes in the manufacture and commercialization of rare cannabinoids. BayMedica is a revenue-stage biotechnology company leveraging its significant expertise in synthetic biology and pharmaceutical chemistry to develop efficient, scalable, and proprietary manufacturing approaches to produce high quality, regulatory-compliant rare cannabinoids for consumer applications. BayMedica is currently commercializing the rare cannabinoid CBC (cannabichromene) as a B2B supplier to distributors and manufacturers marketing products in the health and wellness sector. BayMedica is currently planning additional rare cannabinoid launches for the coming year. In addition to their manufacturing and commercial activities in the health and wellness arena, BayMedica is researching cannabinoid analogs as potential drug candidates for pharmaceutical purposes. Those BayMedica proprietary compounds are based upon the structures of naturally-occurring cannabinoids and are designed to either augment the potential therapeutic effect against specific diseases or enhance product safety, or both.

    • On Thursday, June 17th, InMed Pharmaceuticals (NASDAQ: INM) announced that its continued optimization of IntegraSyn™ has increased the cannabinoid yield to a level of 5 g/L, further improving the economics of this proprietary manufacturing approach in advance of large-scale production. InMed’s cannabinoid yield of 5 g/L significantly exceeds currently reported industry yields. The Company has continued to make important steps to further optimize the IntegraSyn™ manufacturing process, resulting in the improved yield of 5 g/L, surpassing InMed’s previously reported yield levels of 2 g/L, an already commercially viable yield. The impact of improved yield is a significant reduction in the overall cost of manufacturing due to greater amount of cannabinoid produced per batch. InMed is now focused on manufacturing scale-up to larger batch sizes in the second half of calendar year 2021. “We are very excited by these impressive yield levels that further validates the IntegraSyn™ manufacturing approach as a commercially viable solution for large-scale, pharmaceutical-grade GMP production of rare cannabinoids. While we continue to refine the process, we are now focused on advancing the program towards the next key milestones, including the manufacture of our first large-scale batch through a GMP-ready process in the coming months. We continue to believe InMed’s proprietary IntegraSyn™ approach will be one of the most important manufacturing processes for pharma-grade cannabinoids,” stated Eric A. Adams, President and Chief Executive Officer of InMed.

  • Shares of Natural-Killer cell (NKcell) focused biopharmaceutical firm Fate Therapeutics (FATE) closed at $68.43, -9.36% for the week. The 52-wk high is $121.16.
    • After the close on Thursday Aug. 20th,  FATE highlighted positive interim clinical data from the Company’s FT516 and FT596 programs for patients with relapsed / refractory B-cell lymphoma. FT516 is the Company’s universal, off-the-shelf natural killer (NK) cell product candidate derived from a clonal master induced pluripotent stem cell (iPSC) line engineered with a novel high-affinity, non-cleavable CD16 (hnCD16) Fc receptor, which is designed to maximize antibody-dependent cellular cytotoxicity (ADCC), a potent anti-tumor mechanism by which NK cells recognize, bind and kill antibody-coated cancer cells. The Company’s FT596 program incorporates both the hnCD16 Fc receptor and a chimeric antigen receptor (CAR) targeting CD19, which is designed to enable multi-antigen targeting of tumor cells, as well as an IL-15 receptor fusion (IL-15RF) to enhance NK cell activity and survival.
    • August 4th, Fate reported business highlights and financial results for the second quarter ended June 30, 2021. Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics stated, “We are very pleased with the early clinical safety and activity we have observed with our off-the-shelf, iPSC-derived NK cell programs in relapsed / refractory lymphoma and acute myeloid leukemia, where interim Phase 1 data indicate FT516 and FT538 are well tolerated and can deliver complete responses for patients. We look forward to sharing additional clinical data from our FT516 and FT596 programs in B-cell lymphoma at our upcoming investor event. Additionally, treatment of the first patient with FT819, the first-ever iPSC-derived T-cell therapy to undergo clinical investigation, is a landmark achievement and further demonstrates the Company’s leadership in off-the-shelf, iPSC-derived cell therapy and the versatility of its proprietary iPSC Product Platform.”
    • On Aug. 2 Fate announced that the first patient has been treated with FT819, an off-the-shelf chimeric antigen receptor (CAR) T-cell therapy targeting CD19+ malignancies. FT819 is the first-ever CAR T-cell therapy derived from a clonal master induced pluripotent stem cell (iPSC) line, a renewable cell source that enables mass production of high quality, allogeneic CAR T cells with greater product consistency, off-the-shelf availability, and broader patient accessibility. FT819 is engineered with several first-of-kind features designed to improve the safety and efficacy of CAR T-cell therapy.

  • Shares of Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, closed at closed at $3.97, +4.47% for the week.  
    • On September 8th, Edward Woo, analyst at Ascendiant Capital Markets issued an update report titled “Q2 about inline. COVID-19 and breast cancer clinical trials expected to start soon should be catalysts for stock” and raided his P/T to $8.50.
    • On September 7th, Atossa adjourned its special stockholder meeting to 9:00 a.m. Eastern time on October 7, 2021 to allow additional time for stockholders to vote. The Company urges stockholders to vote on the proposal put forth in the proxy statement prior to the new meeting date. The purpose of the special meeting is to approve an increase in authorized shares of common stock, which requires the affirmative vote of a majority of the shares of common stock issued and outstanding as of the record date. While the votes cast to date have been strongly in favor of the proposal (73% of shares voted have been voted in favor), only 58% of the outstanding shares of common stock have been voted with 42% voting in favor of the proposal. Atossa is therefore adjourning the meeting for 30 days to allow additional time for stockholders to vote. Atossa stockholders may vote by calling (833) 786-6488 Monday through Friday 9 a.m. to 9 p.m. Eastern Time.
    • On Thursday, September 2nd, Atossa Therapeutics, Inc. (Nasdaq:ATOS) announced that it has received approval from the Swedish Ethics Review Authority to begin a Phase 2 clinical study of oral Endoxifen for the reduction of mammographic breast density (MBD). MBD is an emerging public health issue affecting more than 10 million women in the United States and many more worldwide. Studies conducted by others have shown that MBD reduces the ability of mammograms to detect cancer and increases the risk of developing breast cancer. Additional studies show a correlation between reducing MBD and a reduction in the incidence of breast cancer. The study, known as the Karisma-Endoxifen study, is a Phase 2, randomized, double-blind, placebo-controlled, dose-response study of Atossa’s proprietary oral Z-Endoxifen in healthy premenopausal women with increased breast density. The primary objective of the study is to determine the dose-response relationship of daily oral Endoxifen on MBD reduction, with secondary endpoints to assess safety, and tolerability, and an exploratory endpoint to assess durability of the MBD changes. It will be conducted in Stockholm and will include approximately 240 participants who will receive daily doses of oral Endoxifen or placebo for six months. South General Hospital in Stockholm will be conducting the study. The study is being led by principal investigator Per Hall, M.D., Ph.D., Head of the Department of Medical Epidemiology and Biostatistics at Karolinska Institutet.

    • On Aug 13th, Atossa announced financial results for the fiscal quarter ended June 30, 2021, and provided an update on recent company developments. “We continue to experience encouraging progress in our MBD and COVID-19 programs, with new regulatory approvals being granted in Sweden for a Phase 2 trial in MBD and authorization in Australia to commence a Phase 2 study of AT-H201 for respiratory illness associated with COVID-19. In the meantime, we continue to enjoy a strong balance sheet, which we have significantly expanded over the last three quarters and will facilitate our development plans over the near term. As we actively explore the possibility for strategic expansion into other areas where we might see near-term milestones and results, we also urge all of our shareholders to exercise their right to vote at our special stockholder’s meeting on September 7, 2021. We urge a vote in favor of the proposal to increase authorized shares, which will provide the Company with the flexibility to issue shares as part of these potential acquisitions, collaborations and partnerships, a common strategy successful biotech companies seeking to grow shareholder value employ in order to create a more attractive opportunity for all. We look forward to continuing to update our stockholders on these opportunities as they develop,” stated Dr. Steven Quay, Atossa’s President and Chief Executive Officer.

  • Shares of  INVO Bioscience, Inc. (INVO), a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of INVOcell®, the world’s only in vivo Intravaginal Culture System, closed at $3.85.
    • On September 9th, INVO Bioscience announced that it has completed the acquisition of a Canadian-based entity that was originally formed to offer INVOcell in Canada. The entity had previously completed a number of important procedures and documentation necessary to establish INVOcell within clinical operations in Canada. INVO Bioscience anticipates leveraging this entity to advance the distribution of INVOcell, and take advantage of the existing product registration which approved the device for sale based on 5-day incubation in the Canadian market. In addition, the Company is initiating the development of joint ventures to establish INVO Centers within the Canadian marketplace, similar to U.S. and Mexico markets, to further drive accelerated adoption of the INVOcell solution while also increasing much needed capacity and patient access within the fertility industry. Steve Shum, CEO of INVO Bioscience, commented, “We believe Canada offers an excellent opportunity to further expand our distribution efforts of INVOcell while also advancing our joint-venture based INVO Center model. With roughly 16% (or 1 in 6) couples in Canada experiencing infertility, a number that has doubled since the 1980s, and with a popultion of 37.74 million, Canada represents a sizable market opportunity. Canada also faces similar issues that hamper other parts of the world, including a large underserved population, access/capacity constraints and affordability challenges. We appreciate the key individuals in Canada that originally created this entity to help promote and bring our INVOcell technology into the marketplace and look forward to bringing greater resources to advance this effort. We anticipate this acquisition will serve as a platform to help accelerate building INVOcell’s presence in Canada.”
    • On September 7th,  INVO Bioscience announced that it has officially opened the Company’s 2nd INVO Center in the United States, based in Atlanta, Georgia after recently opening their first in Birmingham, AL called “Innovative Fertility Specialists, An INVO Center” on August 9th. INVO Centers are further scheduled this year to open in Monterrey, Mexico & the San Francisco Bay Area. This new joint-venture, named “Bloom Fertility, an INVO Center,” will focus on patients in need of advanced fertility care utilizing the efficient, effective, and affordable INVOcell solution. READ THE COMPLETE STORY. 

    • On Sept. 3, INVO Bioscience announced that Dr. Inger Britt Carlsson will be presenting at the Association for Fertility and Reproductive Health (AFRH) virtual conference this year on September 23rd and 24th on the topic of INVOcell® as an efficient, patient-centric and affordable fertility solution for the continent of Africa. “Across the African continent, infertility is on the rise, with an average infertility rate of 10.1% and as high as 32% in some countries. Infertility comes with devastating social, cultural, emotional and economic consequences for young couples in Africa.Unfortunately, accessing basic assisted reproductive technology treatments can be challenging or impossible for couples who have issues conceiving. The INVOcell solution is a low-cost and effective fertility treatment option that can be the answer to this burgeoning dilemma,” said Dr. Carlsson.

    • On August 16th, INVO announced their financial and operating results for the second quarter ended June 30, 2021 and provided a business update. Steve Shum , CEO of INVO stated. “Our team made excellent progress during the second quarter of 2021 toward our key objectives, headlined by last week’s official opening of our first INVO Center practice in Birmingham, AlabamaWe feel INVO is now well positioned for success based on the following core foundational elements developed over the past 2 years. We believe there is a substantial underserved patient population with infertility challenges and a real need to expand access to treatment. In our opinion, this is a multi-billion-dollar market expansion opportunity, and INVOcell is well positioned to address the unmet medical need.”


    • On June 30th, VP Watchlist company, INVO Bioscience, Inc. (NASDAQ: INVO) expanded their North American footprint as they announced on June 30th that they had signed a joint venture agreement in partnership with reproductive specialist Dr. Sue Ellen Carpenter, M.D. through its wholly-owned subsidiary, INVO Centers, LLC, to open an INVO clinic in Atlanta. The clinic, Bloom Fertility, is scheduled to open in the second half of 2021. INVO Bioscience will provide funding for start-up and operating costs and own 40% of the Atlanta Joint Venture. Dr. Sue Ellen Carpenter, MD, is Board Certified in Obstetrics and Gynecology. With over 30 years of experience in reproductive medicine, Dr. Carpenter’s specialties include in vitro fertilization, treating congenital anomalies associated with infertility, as well as endometriosis and polycystic ovarian syndrome. Noted for excellence in her field and a “Top Doctor, Atlanta 2019 and 2020″ she delivers lectures across the country and has published more than a dozen papers on reproduction and fertility. She is an active member of the American Society of Reproductive Medicine (ASRM) as well as the Georgia OB GYN Society. Note that INVO Bioscience has also signed clinic partnerships in Birmingham, Alabama and the San Francisco Bay area earlier this year, along with its Mexico partnership in late 2020, which is scheduled to open later this year. These clinics, through the utilization of the INVOcell technology, in addition to the multiple clinic and distribution partnerships throughout the world are bringing advanced fertility care and much needed expanded access to the millions of underserved people.

Dr. David Sable Portfolio Manager of The Special Situations Fund of AWM Investment Company

    • On May 11, a 13G was filed that confirms that David Sable’s (a former #IVF doc turned portfolio manager) Special Situations Fund of AWM Investment Company increased their ownership to 11.1% or 1,154,153 share ownership of INVO Bioscience (INVO). They held 625k/6.5% as of the 13G filing 2-12-2021. If you are not familiar with them, I believe if you do a relatively small amount sleuthing you will find out that they are one of the most successful multi-billion funds over the last 20-years, especially in finding small undiscovered microchips. I believe that they led the round of $13M at $3.20 a share in November 12, 2020 that pushed INVO uplist to the NASDAQ. Here’s the 13G filing. The company only has 10,424,229 shares issued and outstanding as of March 31, 2021.
    • Industry forecasts suggest that only 1% to 2% of the estimated 150 million infertile couples worldwide are currently being treated. INVO’s mission is to increase access to care and expand infertility treatment across the globe with a goal of improving patient affordability and industry capacity. Since January 2019, INVO Bioscience has signed commercialization agreements in the United States, India, as well as parts of Africa and Eurasia and Mexico for the INVOcell device.

Thanks again for your attention this week. Please continue to share your thoughts, questions, & ideas as we move forward. 

In the meantime, please enjoy the balance of the weekly newsletter’s videos, quotes, updates. 


Symbol Name Last Price Change % Change

Big Movers

Symbol Name Last Price Change % Change

Bond Markets & US Dollar

Symbol Name Last Price Change % Change

Agriculture & Energy

Symbol Name Last Price Change % Change

Biotech & Healthcare

Symbol Name Last Price Change % Change

Consumer Goods & Trends

Symbol Name Last Price Change % Change

Financials & Fintech

Symbol Name Last Price Change % Change

Materials & Natural Resources

Symbol Name Last Price Change % Change

Technology & Beyond

Symbol Name Last Price Change % Change

Investing & Inspiration

  1. “Life is a dream for the wise, a game for the fool, a comedy for the rich, a tragedy for the poor.” – Sholom Aleichem
  2. “The truth is you don’t know what is going to happen tomorrow. Life is a crazy ride, and nothing is guaranteed.” – Eminem
  3. “Man is only great when he acts from passion.” – Benjamin Disraeli
  4. “We need to stop thinking about infrastructure as an economic stimulant and start thinking about it as a strategy. Economic stimulants produce Bridges to Nowhere. Strategic investment in infrastructure produces a foundation for long-term growth.” – Roger McNamee
  5. “We must let go of the life we have planned, so as to accept the one that is waiting for us.” – Joseph Campbell
  6. “Put your heart, mind, and soul into even your smallest acts. This is the secret of success.” – Swami Sivananda
  7. “I can’t change the direction of the wind, but I can adjust my sails to always reach my destination.” – Jimmy Dean
  8. “Companies have too many experts who block innovation. True innovation really comes from perpendicular thinking.” – Peter Diamandis
  9. “By failing to prepare, you are preparing to fail.” – Benjamin Franklin
  10. “We must let go of the life we have planned, so as to accept the one that is waiting for us.” – Joseph Campbell
  11. “We cannot solve our problems with the same thinking we used when we created them.” – Albert Einstein

  12. “When you’re an investor, you can look at the quantitative and qualitative elements of an investment, but there’s a third aspect: What you feel in your gut.” – Kevin O’Leary

  13. “Set your course by the stars, not by the lights of every passing ship.” – Omar N. Bradley
  14. “Do not take life too seriously. You will never get out of it alive.” – Elbert Hubbard
  15. “Education is not only a ladder of opportunity, but it is also an investment in our future.” – Ed Markey 
  16. “Every good painter paints what he is.” – Jackson Pollock
  17. If you believe in yourself and have dedication and pride – and never quit, you’ll be a winner. The price of victory is high but so are the rewards.” – Bear Bryant
  18. “Your mindset matters. It affects everything – from the business and investment decisions you make, to the way you raise your children, to your stress levels and overall well-being.” – Peter Diamandis
  19. “You cannot have a positive life and a negative mind.” – Joyce Meyer 
  20. “Like wildebeest and zebra migration across the Serengeti, investment managers and consultants, too, have a habit of running together and, every now and then, changing direction.” – Sanjaya Baru
  21. “If people are anything but enthusiastic about the information or ideas that they’re sharing, they’re either not that invested in what they’re doing – or they’re not communicating that investment effectively.” – Ana Kasparian 
  22. “Life consists not in holding good cards but in playing those you hold well.” – Josh Billings 
  23. “Friend, there’s no greater investment in life than in being a people builder. Relationships are more important than our accomplishments.” – Joel Osteen
  24. “It’s only natural that the heavy users help contribute to the investment to keep the Web healthy. That is the most important concept of net neutrality.” – Lowell McAdam
  25. “The more sand that has escaped from the hourglass of our life, the clearer we should see through it.” – Jean Paul 
  26. “Eliminate emotion from your investment program.” -John C. Bogle

  27. “Modern medical advances have helped millions of people live longer, healthier lives. We owe these improvements to decades of investment in medical research.” – Ike Skelton

  28. “In every investment, before I get involved or invest, I always see what the mindset of the founder, the CEO, is.” – Zaza Pachulia
  29. “An investment said to have an 80% chance of success sounds far more attractive than one with a 20% chance of failure. The mind can’t easily recognize that they are the same.” – Daniel Kahneman
  30. “The return on investment in global health is tremendous, and the biggest bang for the buck comes from vaccines. Vaccines are among the most successful and cost-effective health investments in history.” – Seth Berkley
  31. “Few things in the world are more powerful than a positive push. A smile. A world of optimism and hope. A ‘you can do it’ when things are tough.” – Richard M. DeVos
  32. To be yourself in a world that is constantly trying to make you something else is the greatest accomplishment.” – Ralph Waldo Emerson
  33. “We all have dreams. But in order to make dreams come into reality, it takes an awful lot of determination, dedication, self-discipline, and effort.”  – Jesse Owens
  34. “The pessimist complains about the wind; the optimist expects it to change; the realist adjusts the sails.” – William Arthur Ward- American Writer, Born 1921
  35. “Once you replace negative thoughts with positive ones, you’ll start having positive results.” – Willie Nelson
  36. “The secret of your future is hidden in your daily routine.” – Mike Murdock
  37. “Work hard for what you want because it won’t come to you without a fight. You have to be strong and courageous and know that you can do anything you put your mind to. If somebody puts you down or criticizes you, just keep on believing in yourself and turn it into something positive.” – Leah LaBelle
  38. “Opportunity is missed by most people because it is dressed in overalls and looks like work”. -Thomas A. Edison
  39. “Education is not only a ladder of opportunity, but it is also an investment in our future.” – Ed Markey
  40. “Human behavior flows from three main sources: desire, emotion, and knowledge.” – Plato

  41. “We are what our thoughts have made us; so take care about what you think. Words are secondary. Thoughts live; they travel far.” – Swami Vivekananda

  42. “Success is not final, failure is not fatal: it is the courage to continue that counts.” – Winston Churchill
  43. “If you don’t know where you are going, any road will get you there.” – Lewis Carroll

  44. “Don’t worry about being a star, worry about doing good work, and all that will come to you.” – Ice Cube

  45. “It is not in the stars to hold our destiny but in ourselves.” – William Shakespeare

  46. “Prediction is very difficult, especially if it’s about the future.” – Niels Bohr

  47. “It is indeed true that the stock market can forecast the business cycle.” -Paul Samuelson

  48. “The wisest rule in investment is: when others are selling, buy. When others are buying, sell. Usually, of course, we do the opposite. When everyone else is buying, we assume they know something we don’t, so we buy. Then people start selling, panic sets in, and we sell too.” – Jonathan Sacks

  49. “What lies behind you and what lies in front of you, pales in comparison to what lies inside of you.” – Ralph Waldo Emerson
  50. Each new generation born is in effect an invasion of civilization by little barbarians, who must be civilized before it is too late.” – Thomas Sowell
  51. “Life is 10% what happens to you and 90% how you react to it.” – Charles R. Swindoll
  52. “The truth is you don’t know what is going to happen tomorrow. Life is a crazy ride, and nothing is guaranteed.” – Eminem
  53. “View health as an investment, not an expense.” – John Quelch
  54. “Opportunity does not knock, it presents itself when you beat down the door.” – Kyle Chandler

  55. If you don’t know where you are going, any road will get you there.” – Lewis Carroll

  56. “Once you replace negative thoughts with positive ones, you’ll start having positive results.” – Willie Nelson

  57. “That which does not kill us makes us stronger.” – Friedrich Nietzsche
  58. “Nothing in life is to be feared, it is only to be understood. Now is the time to understand more, so that we may fear less.” – Marie Curie
  59. “A problem is a chance for you to do your best.”– Duke Ellington
  60. “The best way to predict the future is to create it.” -Peter Drucker
  61. “I’m involved in the stock market, which is fun and, sometimes, very painful.” – Regis Philbin
  62. “Who owns the future? This is the question at the heart of every stock market.” – John Landgraf
  63. “One of the funny things about the stock market is that every time one person buys, another sells, and both think they are astute.” – William Feather
  64. “While I’m sure some millennials are concerned with the ethical issues involved in mining for diamonds, the main reason they steer clear of the gems is because, well, they’re a dumb investment.” – Ana Kasparian
  65. “The wisest rule in investment is: when others are selling, buy. When others are buying, sell. Usually, of course, we do the opposite. When everyone else is buying, we assume they know something we don’t, so we buy. Then people start selling, panic sets in, and we sell too.” – Jonathan Sacks
  66. We must shift our thinking away from short-term gain toward long-term investment and sustainability, and always have the next generations in mind with every decision we make.” –  Deb Haaland

  67. “The only way to have a friend is to be one.” –  Ralph Waldo Emerson

  68. “If you believe in yourself and have dedication and pride – and never quit, you’ll be a winner. The price of victory is high but so are the rewards.” – Bear Bryant

  69. “Investing in women’s lives is an investment in sustainable development, in human rights, in future generations – and consequently in our own long-term national interests.” -Liya Kebede

  70. “Success is not final, failure is not fatal: it is the courage to continue that counts.” – Winston Churchill

  71. “Our greatest glory is not in never falling, but in rising every time we fall.” – Confucius
  72. “Give me a lever long enough and a fulcrum on which to place it, and I shall move the world.” – Archimedes
  73. “Who controls the past controls the future. Who controls the present controls the past.” – George Orwell
  74. “If you get up in the morning and think the future is going to be better, it is a bright day. Otherwise, it’s not.” – Elon Musk
  75. The pessimist complains about the wind; the optimist expects it to change; the realist adjusts the sails.” – William Arthur Ward
  76. “Start where you are. Use what you have. Do what you can.” – Arthur Ashe
  77. “Netflix, Amazon, iTunes – whatever platforms emerge – we are looking at as having the same potential that home video had for the movie business. Which means there are entirely new opportunities to monetize our capital investment in content and do so in ways that work for distributors, for consumers and for creators.” – Bob Iger
  78. “When you have no one to answer to, vendetta as investment strategy is as legitimate as anything.” – Carl Icahn
  79. “No other investment yields as great a return as the investment in education. An educated workforce is the foundation of every community and the future of every economy.” – Brad Henry
  80. “In my view, the biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital. Not only is the mere drop in stock prices not risk, but it is an opportunity. Where else do you look for cheap stocks?” – Li Lu
  81. “Modern medical advances have helped millions of people live longer, healthier lives. We owe these improvements to decades of investment in medical research.”– Ike Skelton
  82. “Stock market goes up or down, and you can’t adjust your portfolio based on the whims of the market, so you have to have a strategy in a position and stay true to that strategy and not pay attention to noise that could surround any particular investment.” – John Paulson
  83. “Your mindset matters. It affects everything – from the business and investment decisions you make, to the way you raise your children, to your stress levels and overall well-being.” – Peter Diamandis
  84. “Inflation destroys savings, impedes planning, and discourages investment. That means less productivity and a lower standard of living.” – Kevin Brady
  85. “Cash – in savings accounts, short-term CDs or money market deposits – is great for an emergency fund. But to fulfill a long-term investment goal like funding your retirement, consider buying stocks. The more distant your financial target, the longer inflation will gnaw at the purchasing power of your money.”  – Suze Orman
  86. “Bitcoin, in the short or even long term, may turn out be a good investment in the same way that anything that is rare can be considered valuable. Like baseball cards. Or a Picasso.” – Andrew Ross Sorkin
  87. “I think you have to learn that there’s a company behind every stock and there’s only one real reason why stocks go up. Companies go from doing poorly to doing well or small companies grow to large companies.” – Peter Lynch
  88. “Historically, there has been a bull market in the commodities every 20 or 30 years.” – Jim Rogers
  89. “The markets generally are unpredictable, so that one has to have different scenarios. The idea that you can actually predict what’s going to happen contradicts my way of looking at the market.” – George Soros
  90. “Stop trying to predict the direction of the stock market, the economy or the elections.” – Warren Buffett
  91. “An important key to investing is to remember that stocks are not lottery tickets.” – Peter Lynch
  92. “Learn everyday, but especially from the experiences of others. It’s cheaper!” – John Bogle
  93. “When purchasing depressed stock in troubled companies, seek out the ones with the superior financial positions and avoid the ones with loads of bank debt.” – Peter Lynch
  94. “No stock price is too low for bears or too high for bulls.” –  John F. Heerdink, Jr.
  95. “Investment is most successful when it is most businesslike.” – Ben Graham
  96. “Value stocks are about as exciting as watching grass grow, but have you ever noticed just how much your grass grows in a week?” – Christopher Browne
  97. “Even the intelligent investor is likely to need considerable willpower to keep from following the crowd.” – Benjamin Graham
  98. “Individual who cannot master their emotions are ill-suited to profit from the investment process.” – Benjamin Graham
  99. “I made my first investment at age eleven. I was wasting my life until then.” – Warren Buffet
  100. “I don’t look to jump over seven-foot bars; I look around for one-foot bars that I can step over.” — Warren Buffett
  101. “There are only three measurements that tell you nearly everything you need to know about your organization’s overall performance: employee engagement, customer satisfaction, and cash flow. It goes without saying that no company, small or large, can win over the long run without energized employees who believe in the mission and understand how to achieve it.” – Jack Welch, former CEO of GE
  102. “Opportunities come infrequently. When it rains gold, put out the bucket, not the thimble” ― Warren Buffett
  103. “If you buy things you do not need, soon you will have to sell things you need.” – Warren Buffet
  104. “How many millionaires do you know who have become wealthy by investing in savings accounts? I rest my case.” — Robert G. Allen
  105. “It’s far better to buy a wonderful company at a fair price, than a fair company at a wonderful price.” – Warren Buffett
  106. “A market downturn doesn’t bother us. It is an opportunity to increase our ownership of great companies with great management at good prices.” — Warren Buffett
  107. “Every once in a while, the market does something so stupid it takes your breath away.” — Jim Cramer
  108. “The person who starts simply with the idea of getting rich won’t succeed; you must have a larger ambition.” — John D. Rockefeller
  109. “Know what you own, and know why you own it.” – Peter Lynch
  110. “Although it’s easy to forget sometimes, a share is not a lottery ticket… it’s part ownership of a business.” – Peter Lynch
  111. “Wise spending is part of wise investing. And it’s never too late to start.” – Rhonda Katz

  112. “Invest for the long haul. Don’t get too greedy and don’t get too scared.” – Shelby M.C. Davis

  113. “Fear incites human action far more urgently than does the impressive weight of historical evidence.”
    -Jeremy Siegel

  114. With a good perspective on history, we can have a better understanding of the past and present, and thus a clear vision of the future.” — Carlos Slim Helu
  115. “If we like a business, we’re going to buy as much of it as we can and keep it as long as we can. And when we change our mind, we don’t take half measures.” – Warren Buffett
  116. “The most contrarian thing of all is not to oppose the crowd but to think for yourself.” — Peter Thiel
  117. “Never depend on a single income, make an investment to create a second source.” Warren Buffet“Games are won by players who focus on the playing field –- not by those whose eyes are glued to the scoreboard.” ― Warren Buffett
  118. “The key to making money in stocks is not to get scared out of them.” – Peter Lynch
  119. “Courage taught me no matter how bad a crisis gets … any sound investment will eventually pay off.” — Carlos Slim Helu
  120. “Investing puts money to work. The only reason to save money is to invest it.” – Grant Cardone
  121. “As time goes on, I get more and more convinced that the right method of investment is to put fairly large sums into enterprises which one thinks one knows something about and in the management of which one thoroughly believes.” — John Maynard Keynes
  122. “Given a 10% chance of a 100 times payoff, you should take that bet every time.” — Jeff Bezos
  123. “Money is always eager and ready to work for anyone who is ready to employ it.” ― Idowu Koyenikan
  124. “The secret to investing is to figure out the value of something – and then pay a lot less.” – Joel Greenblatt
  125. “We don’t have an analytical advantage, we just look in the right place.” – Seth Klarman
  126. “Men, it has been well said, think in herds. It will be seen that they go mad in herds, while they only recover their senses slowly, and one by one.” – Charles Mackay
  127. “It’s not whether you’re right or wrong that’s important, but how much money you make when you’re right and how much you lose when you’re wrong.” – George Soros
  128. “In investing, what is comfortable is rarely profitable.” — Robert Arnott
  129. “Don’t look for the needle in the haystack. Just buy the haystack!” — John Bogle
  130. “No Price is too low for a bear or too high for a bull.” — Anonymous
  131. “Investment is an asset or item that is purchased with the hope that it will generate income or appreciate in the future.” — Anonymous
  132. “Behind every stock is a company. Find out what it’s doing.” — Peter Lynch
  133. “Wise spending is part of wise investing. And it’s never too late to start.” –Rhonda Katz
  134. “If there is one common theme to the vast range of the world’s financial crises, it is that excessive debt accumulation, whether by the government, banks, corporations, or consumers, often poses greater systemic risks than it seems during a boom.” — Carmen Reinhart
  135. “It amazes me how people are often more willing to act based on little or no data than to use data that is a challenge to assemble.” ― Robert Shiller
  136. “A bull market is like sex. It feels best just before it ends.” — Barton Biggs
  137. “The investor’s chief problem — even his worst enemy — is likely to be himself.” — Benjamin Graham
  138. “No profession requires more hard work, intelligence, patience, and mental discipline than successful speculation.” – Robert Rhea
  139. “The most contrarian thing of all is not to oppose the crowd but to think for yourself.” — Peter Thiel
  140. “Money is like a sixth sense – and you can’t make use of the other five without it.” – William Somerset Maugham
  141. “Compound interest is the eighth wonder of the world. He who understands it, earns it. He who doesn’t, pays it.” — Albert Einstein
  142. “The stock market is a device for transferring money from the impatient to the patient.” – Warren Buffett
  143. “Thousands of experts study overbought indicators, head-and-shoulder patterns, put-call ratios, the Fed’s policy on money supply…and they can’t predict markets with any useful consistency, any more than the gizzard squeezers could tell the Roman emperors when the Huns would attack.” – Peter Lynch
  144. “Investing puts money to work. The only reason to save money is to invest it.” – Grant Cardone
  145. “Formal education will make you a living; self-education will make you a fortune.” – Jim Rohn
  146. “You cannot save time for your future use however you can invest time for your future.” – John F. Heerdink, Jr. 
  147. “We always live in an uncertain world. What is certain is that the United States will go forward over time.” – Warren Buffett
  148. “Never test the depth of the river with both of your feet.” – Warren Buffet
  149. “Know what you own, and know why you own it.” – Peter Lynch
  150. “Liquidity is only there when you don’t need it.” -Old Proverb
  151. “There is no such thing as no risk. There’s only this choice of what to risk, and when to risk it.” – Nick Murray
  152. “If you want to be a millionaire, start with a billion dollars and launch a new airline.” – Richard Branson
  153. Fear incites human action far more urgently than does the impressive weight of historical evidence.” – Jeremy Siegel
  154. “In investing, what is comfortable is rarely profitable.” – Robert Arnott
  155. “Spend each day trying to be a little wiser than you were when you woke up.” – Charlie Munger
  156. “The entrance strategy is actually more important than the exit strategy.” – Edward Lampert
  157. “The rivers don’t drink their own water; Trees don’t eat their own fruits. The sun does not shine for itself, And flowers do not spread their fragrance For themselves. Living for others is a rule of nature” – PopeFrancis
  158. “It is impossible to produce superior performance unless you do something different from the majority.” – John Templeton
  159. “Inaction and patience are almost always the wisest options for investors in the stock market.” – Guy Spier
  160. “Remember that the stock market is a manic depressive.”  – Warren Buffett
  161. “An investment in knowledge pays the best interest.” – Benjamin Franklin
  162. “I believe the returns on investment in the poor are just as exciting as successes achieved in the business arena, and they are even more meaningful!” -Bill Gates
  163. “Every portfolio benefits from bonds; they provide a cushion when the stock market hits a rough patch. But avoiding stocks completely could mean your investment won’t grow any faster than the rate of inflation.” – Suze Orman
  164. “The tax on capital gains directly affects investment decisions, the mobility and flow of risk capital… the ease or difficulty experienced by new ventures in obtaining capital, and thereby the strength and potential for growth in the economy.” – John F. Kennedy
  165. “If all the economists were laid end to end, they’d never reach a conclusion.
    -George Bernard Shaw
  166. “The riskiest thing we can do is just maintain the status quo. I get up at 4:30 in the morning, seven days a week, no matter where I am in the world. I think it is important for people who are given leadership roles to assume that role immediately. What I’ve really learned over time is that optimism is a very, very important part of leadership.” – Bob Iger, Former Ceo of Disney
  167. “In the short run, the market is a voting machine. But in the long run, it is a weighing machine.” – Ben Graham
  168. “In investing, what is comfortable is rarely profitable.” -Robert Arnott
  169. “The fundamental law of investing is the uncertainty of the future.” -Peter Bernstein
  170. “How many millionaires do you know who have become wealthy by investing in savings accounts?” -Robert G Allen
  171. “Greed is all right, by the way. I think greed is healthy. You can be greedy and still feel good about yourself.”-Ivan Boesky
  172. Michael Marcus taught me one other thing that is absolutely critical: You have to be willing to make mistakes regularly; there is nothing wrong with it. Michael taught me about making your best judgment, being wrong, making your next best judgment, being wrong, making your third best judgment, and then doubling your money.” -Bruce Kovner
  173. “The policy of being too cautious is the greatest risk of all.” -Jawaharlal Nehru
  174. “I talk about macro themes a lot because they are fun to talk about, but it is the risk management that is the most important thing. The risk control is all bottom-up. I structured the business right from the get-go so that we would have lots of diversification.” -Michael Platt
  175. “Blaming speculators as a response to financial crisis goes back at least to the Greeks. It’s almost always the wrong response.” -Larry Summers
Symbol Name Last Price Change % Change


Please consider viewing these interesting videos: